Occupe actuellement des postes chez Adaptimmune Therapeutics PLC, Medimmune LLC and Ardelyx Inc
Position | Company | Period |
---|---|---|
Chief Operating Officer | Adaptimmune Therapeutics PLC | 15 mars 2017 - |
Executive Vice President, General Counsel | Medimmune LLC | None - |
Independent Director | Ardelyx Inc | 26 octobre 2015 - |
Executive Vice President, General Counsel | Infinity Pharmaceuticals Inc | 19 octobre 2015 - 2 septembre 2016 |
Acting Chief Operating Officer | Salix Pharmaceuticals Ltd | 30 janvier 2015 - 1 avril 2015 |
Rechercher
Date de notification | Date de transaction | A/V Type de transaction |
Nb. d'actions Prix Valeur |
Nombre d'actions | Prix | Valeur totale | Détails | |
---|---|---|---|---|---|---|---|---|
2024-01-17 | 2024-01-17 |
Adaptimmune Therapeutics PLC
(ADAP)
|
V Vente |
13 599
-40.2%
0,679 152 USD |
13 599 -40.2% | 0,67 | 9 152 USD | |
2024-01-17 | 2024-01-17 |
Adaptimmune Therapeutics PLC
(ADAP)
|
V Vente |
5 309
-40.5%
0,673 573 USD |
5 309 -40.5% | 0,67 | 3 573 USD | |
2024-01-12 | 2024-01-12 |
Adaptimmune Therapeutics PLC
(ADAP)
|
V Vente |
5 220
-39.9%
0,854 458 USD |
5 220 -39.9% | 0,85 | 4 458 USD | |
2024-01-12 | 2024-01-11 |
Adaptimmune Therapeutics PLC
(ADAP)
|
V Vente |
4 009
-39.6%
0,843 354 USD |
4 009 -39.6% | 0,84 | 3 354 USD | |
2023-01-17 | 2023-01-17 |
Adaptimmune Therapeutics PLC
(ADAP)
|
V Vente |
4 440
-37.9%
1,868 250 USD |
4 440 -37.9% | 1,86 | 8 250 USD | |
2023-01-12 | 2023-01-12 |
Adaptimmune Therapeutics PLC
(ADAP)
|
V Vente |
4 973
-38.0%
1,718 484 USD |
4 973 -38.0% | 1,71 | 8 484 USD | |
2023-01-04 | 2023-01-04 |
Adaptimmune Therapeutics PLC
(ADAP)
|
V Vente |
3 584
-38.3%
1,696 071 USD |
3 584 -38.3% | 1,69 | 6 071 USD | |
2022-01-18 | 2022-01-18 |
Adaptimmune Therapeutics PLC
(ADAP)
|
V Vente |
4 368
-37.3%
3,1913 942 USD |
4 368 -37.3% | 3,19 | 13 942 USD | |
2022-01-13 | 2022-01-12 |
Adaptimmune Therapeutics PLC
(ADAP)
|
V Vente |
2 248
-37.5%
3,547 967 USD |
2 248 -37.5% | 3,54 | 7 967 USD | |
2022-01-13 | 2022-01-11 |
Adaptimmune Therapeutics PLC
(ADAP)
|
V Vente |
3 770
-37.3%
3,5613 409 USD |
3 770 -37.3% | 3,56 | 13 409 USD | |
2022-01-05 | 2022-01-04 |
Adaptimmune Therapeutics PLC
(ADAP)
|
V Vente |
3 490
-37.3%
4,0614 184 USD |
3 490 -37.3% | 4,06 | 14 184 USD | |
2021-01-12 | 2021-01-12 |
Adaptimmune Therapeutics PLC
(ADAP)
|
V Vente |
2 234
-37.2%
6,1513 744 USD |
2 234 -37.2% | 6,15 | 13 744 USD | |
2021-01-05 | 2021-01-04 |
Adaptimmune Therapeutics PLC
(ADAP)
|
V Vente |
3 499
-37.4%
5,3318 642 USD |
3 499 -37.4% | 5,33 | 18 642 USD | |
2020-12-15 | 2020-12-14 |
Adaptimmune Therapeutics PLC
(ADAP)
|
A Achat |
207 000
+266.0%
0,69143 824 USD |
207 000 +266.0% | 0,69 | 143 824 USD | |
2020-01-15 | 2020-01-14 |
Adaptimmune Therapeutics PLC
(ADAP)
|
V Vente |
2 397
-39.9%
5,1312 308 USD |
2 397 -39.9% | 5,13 | 12 308 USD | |
2020-01-07 | 2020-01-06 |
Adaptimmune Therapeutics PLC
(ADAP)
|
V Vente |
3 731
-39.8%
1,204 477 USD |
3 731 -39.8% | 1,20 | 4 477 USD | |
2019-01-16 | 2019-01-14 |
Adaptimmune Therapeutics PLC
(ADAP)
|
V Vente |
2 271
-37.8%
5,3712 194 USD |
2 271 -37.8% | 5,37 | 12 194 USD |